Pfizer Builds Global GLP-1 Strategy With up to $495M Sciwind Deal
Even after shelling out $10 billion late last year to acquire Metsera, Pfizer appears to still be hungry for obesity deals. Tuesday, the pharma secured an exclusive Chinese commercialization license for Sciwind Biosciences’ China-approved GLP-1 injection …